← All trials

NCT05626439

Phase 1Interventional

Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

View on ClinicalTrials.gov ↗

Timeline

Start date
Dec 7, 2022
Primary completion
Feb 15, 2023
Completion date
Feb 15, 2023
First posted
Nov 23, 2022
Last posted
Dec 1, 2022
Enrollment
20
Arms / groups
2 / —
Source
AACT · ctgov ingestion

Sponsors

  • UCBLead sponsor
  • UCBStudy director

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.